Changes to CredibleMeds® lists: Olodaterol and Solifenacin

The safe use of the CredibleMeds^® lists of medications requires that the user have the most up-to-date lists and be aware when changes have been made.  Therefore, we wish to inform you of the following:  

We have evaluated the evidence for the bronchodilator olodaterol (brand name Striverdi Respimat^®) and found that is has actions which pose a risk for some patients with inherited long QT syndrome.  Therefore, we have added olodaterol to the list of Drugs to Avoid, if at all possible, by patients with congenital long QT syndrome.

We also re-evaluated solifenacin (brand name Vesicare^®), a drug used to treat bladder spasm, currently on the Conditional Risk (CR) list.  While there continues to be substantial evidence for QT prolongation, the sum of the available evidence for TdP is limited.  Therefore, we are recommending that solifenacin be moved from the Conditional Risk list to the Possible Risk list.

Also, you may want to check out the new and improved drug search function for the lists of drugs at https://dev.crediblemeds.org/druglist

Thank you for your support of CredibleMeds.org.